Array Biopharma Inc.

Amgen Inc.

Aventis Pharma Deutschland, Gmbh

Aventis Pharmaceuticals Inc.

Ventirx Pharmaceuticals, Inc.

Sanofi-a Ventis Deutschland Gmbh

Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharmaceuticals Products Inc.

Robert D Groneberg

Joseph P Lyssikatos

Laurence Edward Burgess

Martha E Rodriguez

Darren Martin Harvey

George A Doherty

David A Mareska

Christopher J Burns

James P Rizzi

Joseph M Salvino

Ellen Ruth Laird

Mark C Munson

Charles Todd Eary

Daniel Gerard McGarry

Jian Jeffrey Chen

Qingyian Liu

Kevin Chao Yang

Christopher Harold Fotsch

Kent W Neuenschwander

Nianhe Han

Robert L Morris

Robert Hershberg

Aiwen Li

Gregory Bernard Poli

Eli M Wallace

William R Ewing

Stevan Wakefield Djuric

Qian Zhao

Alfred P Spada

Timothy Francis Gallagher

Mark Henry Norman

Xicheng David Sun

Wei He

Heinz W Pauls

Thomas T Nguyen

Michael R Myers

John Joseph Gaudino

Stephen M Condon

Scott S Harried

Anthony C Scotese

Timothy S Kercher

Mark Laurence Boys

Chester Chenguang Yuan

Joseph M Karpinski

Wenyuan Qian

Hong Woon Yang

Richard F Labaudiniere

Zachary Jones

Gerard M McGeehan

Anne Minnich

Mark A Bobko

C Todd Eary

Michael F Kelley

Derin C D'amico

Gregory Dietsch

Daniel John Watson

Rana Nomak

Babak Riahi

Benny C Askew, Jr

James Zhan

James Jeffry Howbert

Youngboo Kim

Litao Zhang

Zaid Jayyosi

Yong Mi Choi-Sledeski

Kaustav Biswas

Jiawang Zhu

Chang Rao

Jeremy J Hans

Barbara Hanney

Lily Huang

Ganghyeok Kim

Andras Toro

Jean-Francois Sabuco

Michael R Becker

Thomas Caulfield

Matthew M Morrissette

John Ziqi Jiang

John W Ullrich

Rose Mappilakunnel Mathew

Christopher F Kraser

Guy Vigers

Devan Balachari

Eugene Tarlton

Roderick S Davis

John E Airey

Fran&ccedil;ois-Fr&eacute;d&eacute;ric Clerc

Daniel No&euml;l Andr&eacute; Bezard

Thomas J Caulfield

Michael O'Sullivan

Stephen Condon

Steven M Condon

Gerald M McGeehan

Mark Bobko

Laurence E Burges

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

Substituted benzoazepines as toll-like receptor modulators

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R, R, R, R, R, R, R, Xand Xhave the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

Piperidine-containing compounds and use thereof

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.

8-substituted benzoazepines as toll-like receptor modulators

The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases. 

Kinase inhibitors and methods of use thereof

A compound of Formula II and salts thereof are useful in the preparation of a compound of Formula I and pharmaceutically acceptable salts and prodrugs thereof.

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.

P38 inhibitors and methods of use thereof

The use of diaryl acid derivatives of formula (I)or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

Therapeutic uses of di-aryl acid derivatives

Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Compounds and methods of use

Cyclic amine derivatives and methods of use

Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R, R, R, and Rare as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus 

Preparation of phosphatase inhibitors

The use of triaryl acid derivatives of formula (I)and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

Therapeutic uses of tri-aryl acid derivatives

Growing community of inventors

Boulder, CO, United States of America

Robert D Groneberg